Clinical trial

Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)

NCT05946148

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Empagliflozin Normalized identity: empagliflozinView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Dulaglutide Normalized identity: dulaglutideView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Control Rx Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2018-06-01

PhaseN/A

Conditions

Non-Alcoholic Fatty Liver Diseaseverified · MONDO: metabolic dysfunction-associated steatotic liver disease

Liver Steatosisunresolved

Interventions

EmpagliflozinDRUG · verified · RxNorm: empagliflozin

DulaglutideDRUG · verified · RxNorm: dulaglutide

Control RxDRUG

Sponsors & collaborators

National and Kapodistrian University of Athenslead sponsor

Alexandra Hospital, Athens, Greececollaborator

Hippocration General Hospitalcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05946148 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.